The term metastatic castration-resistant prostate cancer (mCRPC) refers to a cancer that has spread (metastasized) beyond your prostate gland and for which hormone therapy is no longer effective in ...

A common clinical question for medical oncologists treating metastatic castration-resistant prostate cancer is, should patients who previously received docetaxel and progress on it, reuse docetaxel or ...

Two types of androgen deprivation therapy (ADT) had different effects on coronary atherosclerosis in a small randomized trial ...

Hormone treatment, also known as androgen deprivation therapy (ADT), is a cornerstone of treatment for advanced prostate cancer. Hormone treatment decreases prostate cancer growth by lowering ...

In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...

Docetaxel rechallenge significantly improved survival compared with cabazitaxel in certain men with metastatic ...

Metastasis-directed therapy for oligometastatic prostate cancer was associated with improved outcomes in a systematic review and meta-analysis.

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial This open-label, 2-cohort, phase II trial ...

But an association with improved overall survival failed to reach statistical significance ...

Prostate cancer has been of the major areas of research for radioligand therapies. Last year, Novartis officials estimated that the March 28, 2025, FDA approval for Pluvicto in metastatic ...